{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:27:02Z","timestamp":1792661222675,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T00:00:00Z","timestamp":1361577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00702-013-0998-9","type":"journal-article","created":{"date-parts":[[2013,2,22]],"date-time":"2013-02-22T12:28:02Z","timestamp":1361536082000},"page":"1345-1353","source":"Crossref","is-referenced-by-count":60,"title":["Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin\u00ae) injections in blepharospasm"],"prefix":"10.1007","volume":"120","author":[{"name":"Xeomin US Blepharospasm Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Truong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Gollomp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"LeWitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Hanschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,23]]},"reference":[{"key":"998_CR1","unstructured":"Allergan, Inc. (2011) Botox\u00ae US Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5232lbl.pdf . Accessed 18 June 2012"},{"key":"998_CR2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","volume":"64","author":"R Benecke","year":"2005","unstructured":"Benecke R, Jost WH, Ka\u00f1ovsk\u00fd P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949\u20131951","journal-title":"Neurology"},{"key":"998_CR3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","volume":"308","author":"CL Comella","year":"2011","unstructured":"Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 308:103\u2013109","journal-title":"J Neurol Sci"},{"key":"998_CR4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00004356-199703000-00004","volume":"20","author":"K Daly","year":"1997","unstructured":"Daly K (1997) Blepharospasm: an Australian survey. Int J Rehabil Res 20:41\u201350","journal-title":"Int J Rehabil Res"},{"key":"998_CR5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.toxicon.2009.03.010","volume":"54","author":"J Frevert","year":"2009","unstructured":"Frevert J (2009) Xeomin is free from complexing proteins. Toxicon 54:697\u2013701","journal-title":"Toxicon"},{"key":"998_CR6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","volume":"10","author":"J Frevert","year":"2010","unstructured":"Frevert J (2010) Content of botulinum neurotoxin in botox\u00ae\/vistabel\u00ae, dysport\u00ae\/azzalure\u00ae, and xeomin\u00ae\/bocouture\u00ae. Drugs R D 10:67\u201373","journal-title":"Drugs R D"},{"key":"998_CR7","first-page":"325","volume":"4","author":"J Frevert","year":"2010","unstructured":"Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325\u2013332","journal-title":"Biologics"},{"key":"998_CR8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H G\u00f6schel","year":"1997","unstructured":"G\u00f6schel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies\u2014therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"998_CR9","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1212\/01.wnl.0000327601.46315.85","volume":"71","author":"M Hallett","year":"2008","unstructured":"Hallett M, Evinger C, Jankovic J, Stacy M (2008) BEBRF International Workshop. Update on blepharospasm: report from the BEBRF International Workshop. Neurology 71:1275\u20131282","journal-title":"Neurology"},{"key":"998_CR10","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/IAI.64.5.1589-1594.1996","volume":"64","author":"K Inoue","year":"1996","unstructured":"Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K, Oguma K (1996) Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 64:1589\u20131594","journal-title":"Infect Immun"},{"key":"998_CR11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","volume":"37","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Orman J (1987) Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37:616\u2013623","journal-title":"Neurology"},{"key":"998_CR12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.22368","volume":"24","author":"J Jankovic","year":"2009","unstructured":"Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G (2009) Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 24:407\u2013413","journal-title":"Mov Disord"},{"key":"998_CR13","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","volume":"26","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Comella C, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm\u2014a randomized trial. Mov Disord 26:1521\u20131528","journal-title":"Mov Disord"},{"key":"998_CR14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","volume":"32","author":"P Ka\u00f1ovsk\u00fd","year":"2009","unstructured":"Ka\u00f1ovsk\u00fd P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, Grafe S (2009) Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 32:259\u2013265","journal-title":"Clin Neuropharmacol"},{"key":"998_CR15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","volume":"43","author":"P Ka\u00f1ovsk\u00fd","year":"2011","unstructured":"Ka\u00f1ovsk\u00fd P, Slawek J, Denes Z, Platz T, Comes G, Grafe S, Pulte I (2011) Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med 43:486\u2013492","journal-title":"J Rehabil Med"},{"key":"998_CR16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00702-007-0768-7","volume":"115","author":"C Kenney","year":"2008","unstructured":"Kenney C, Jankovic J (2008) Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 115:585\u2013591","journal-title":"J Neural Transm"},{"key":"998_CR17","unstructured":"Merz Pharmaceuticals GmbH (2011) Xeomin\u00ae US Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125360s007lbl.pdf . Accessed 19 June 2012"},{"key":"998_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenk\u00e4mper","year":"2006","unstructured":"Roggenk\u00e4mper P, Jost WH, Bihari K, Comes G, Grafe S (2006) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303\u2013312","journal-title":"J Neural Transm"},{"issue":"Suppl 8","key":"998_CR19","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1002\/mds.20021","volume":"19","author":"D Sesardic","year":"2004","unstructured":"Sesardic D, Jones RG, Leung T, Alsop T, Tierney R (2004) Detection of antibodies against botulinum toxins. Mov Disord 19(Suppl 8):S85\u2013S91","journal-title":"Mov Disord"},{"key":"998_CR20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","volume":"15","author":"KD Sethi","year":"2012","unstructured":"Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:419\u2013423","journal-title":"J Med Econ"},{"key":"998_CR21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","volume":"14","author":"Truong D, Comella C, Fernandez HH, Ondo WG, Dysport Benign Essential Blepharospasm Study Group","year":"2008","unstructured":"Truong D, Comella C, Fernandez HH, Ondo WG, Dysport Benign Essential Blepharospasm Study Group (2008) Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 14:407\u2013414","journal-title":"Parkinsonism Relat Disord"},{"key":"998_CR22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.parkreldis.2006.06.002","volume":"12","author":"DD Truong","year":"2006","unstructured":"Truong DD, Jost WH (2006) Botulinum toxin: clinical use. Parkinsonism Relat Disord 12:331\u2013355","journal-title":"Parkinsonism Relat Disord"},{"key":"998_CR23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","volume":"118","author":"B Wabbels","year":"2011","unstructured":"Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenk\u00e4mper P (2011) Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 118:233\u2013239","journal-title":"J Neural Transm"},{"key":"998_CR24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0885-3924(00)00146-9","volume":"20","author":"J Wissel","year":"2000","unstructured":"Wissel J, M\u00fcller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W (2000) Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20:44\u201349","journal-title":"J Pain Symptom Manage"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-0998-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-013-0998-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-0998-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T18:46:53Z","timestamp":1595443613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-013-0998-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,23]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["998"],"URL":"https:\/\/doi.org\/10.1007\/s00702-013-0998-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,23]]}}}